Tag: rilzabrutinib
Sanofi: Rilzabrutinib Phase III Study Reaches Primary Endpoint
Published on 04/23/2024 at 7:05 a.m. April 23 (Reuters) – Sanofi SA: *PHASE III LUNA 3 STUDY OF RILZABRUTINIB FOR THE TREATMENT…
Sanofi: Phase III LUNA 3 study of rilzabrutinib for the treatment of immune thrombocytopenia met its primary endpoint
By Claude Leguilloux Published on 04/23/2024 at 7:42 a.m. Photo credit © Sanofi Corporate (Boursier.com) — Positive…
Sanofi Presents Phase II Results of Rilzabrutinib at AAAAI Congress
By Alexandra Saintpierre Published on 02/25/2024 at 6:18 p.m. Photo credit © Sanofi (Boursier.com) — Breaking data presented…
Press release: Phase II results show that rilzabrutinib can quickly reduce the severity of itching caused by chronic spontaneous urticaria and significantly improve disease activity in adults – 02/24/2024 at 3:51 p.m.
Phase II Results Show Rilzabrutinib Rapidly Reduces Severity of Itching Caused by Chronic Spontaneous Urticaria and Significantly Improves Disease Activity in Adults Breaking data presented at the 2024 AAAAI Congress…
Sanofi: positive results for a study on rilzabrutinib as a treatment for IPT
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Thursday positive results for a phase I/II study evaluating rilzabrutinib for the treatment of immune thromobocytopenia (IPT) in adults. Results published in…